首页> 外文期刊>Cyclodextrin news >Avermectin, the Nobel Prize Winner Drug in Cyclodextrin-Enabled Formulations
【24h】

Avermectin, the Nobel Prize Winner Drug in Cyclodextrin-Enabled Formulations

机译:Avermectin,诺贝尔奖获得者的诺贝尔奖获得者药物

获取原文
获取原文并翻译 | 示例
           

摘要

The 2015 Nobel prize in Physiology and Medicine was shared by Y. Tu for the discovery of the antimalarial artemisinin (see the 2016 March issue of the Cyclodextrin News) and William C. Campbell and Satoshi ōmura who discovered avermectin, the derivatives of which have radically lowered the incidence of River Blindness and Lymphatic Filariasis, as well as showing efficacy against an expanding number of other parasitic diseases. [1] It was ōmura of Kitasato University (Tokyo) who identified avermectin from the bacterium Streptomyces avermitilis and Campbell of the Merck Institute for Therapeutic Research who purified avermectin from the cultures and discovered ivermectin, a derivative of greater potency and lower toxicity. [2]
机译:2015年诺贝尔生理学和医学奖是由Y. tu共享的,以发现抗疟药青蒿素(请参阅2016年3月的Cyclodextrin News)和William C. Campbell和Satoshi mura,他们发现了Avermectin,其范围有射频的衍生物 降低了河流失明和淋巴丝虫病的发病率,并显示出对其他寄生虫疾病不断扩大的功效。 [1]是基塔萨托大学(东京)的ōmura,从梅克氏链霉菌菌属菌群和默克治疗研究所的坎贝尔中鉴定出了平敏蛋白,从培养物中纯化了平染蛋白,并发现了伊维法蛋白,并发现了伊维尔梅尔蛋白,是一种效率和较低毒性和较低毒性和较低的毒性和较低的毒性。 [2]

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号